J Pathol Transl Med.  2022 May;56(3):115-125. 10.4132/jptm.2022.04.13.

Neuropathologic features of central nervous system hemangioblastoma

• Yoda RA
• Cimino PJ

• KMID: 2529802
• DOI: http://doi.org/10.4132/jptm.2022.04.13

Abstract

Hemangioblastoma is a benign, highly vascularized neoplasm of the central nervous system (CNS). This tumor is associated with loss of function of the VHL gene and demonstrates frequent occurrence in von Hippel-Lindau (VHL) disease. While this entity is designated CNS World Health Organization grade 1, due to its predilection for the cerebellum, brainstem, and spinal cord, it is still an important cause of morbidity and mortality in affected patients. Recognition and accurate diagnosis of hemangioblastoma is essential for the practice of surgical neuropathology. Other CNS neoplasms, including several tumors associated with VHL disease, may present as histologic mimics, making diagnosis challenging. We outline key clinical and radiologic features, pathophysiology, treatment modalities, and prognostic information for hemangioblastoma, and provide a thorough review of the gross, microscopic, immunophenotypic, and molecular features used to guide diagnosis.

Keyword

Hemangioblastoma; von Hippel-Lindau disease; Neuropathology; Cerebellar neoplasms; Brain

Figure

• 

  Fig. 1. Representative brain magnetic resonance imaging for hemangioblastoma. (A) T2/FLAIR and (B) T1-weighted post-contrast sequences showing a posterior fossa cystic mass with a mural enhancing nodule.

• 

  Fig. 2. Intraoperative direct smear and frozen section findings of central nervous system hemangioblastoma. Representative intraoperative analysis of hemangioblastoma demonstrating (A) resistance to smear cytological preparation and (B) the presence of cells with vacuolated cytoplasm on frozen section.

• 

  Fig. 3. Histopathological features of central nervous system hemangioblastoma. Representative permanent sections highlighting how hemangioblastomas are highly vascular neoplasms and may contain (A) abundant capillaries, (B) large branching vessels, and/or (C) areas of hemorrhage. (D) Stromal cells contain abundant foamy vacuolated cytoplasm. (E) Nuclear atypia may be seen in some stromal cells. (F) Hemangioblastomas often from well-demarcated border with adjacent brain parenchyma.

• 

  Fig. 4. Immunohistochemical features of central nervous system hemangioblastoma. Immunohistochemical profiling for hemangioblastoma usually includes positivity for (A) inhibin alpha, (B) CAIX, and (C) CD31, with negativity for renal markers such as (D) PAX8.

Reference

References

1. Tse JY, Wong JH, Lo KW, Poon WS, Huang DP, Ng HK. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol. 1997; 107:459–66.

2. WHO Classification of Tumours Editorial Board. Central nervous system tumours. 5th ed. Vol. 6 [Internet]. Lyon: International Agency for Research on Cancer;2021. [cited 2022 Mar 10]. Available from: https://tumourclassification.iarc.who.int/chapters/45.

3. Yin X, Duan H, Yi Z, Li C, Lu R, Li L. Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system: analysis based on the Surveillance, Epidemiology, and End Results Database. Front Oncol. 2020; 10:570103.

4. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23:iii1–105.

5. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol. 1999; 1:14–25.

6. Constans JP, Meder F, Maiuri F, Donzelli R, Spaziante R, de Divitiis E. Posterior fossa hemangioblastomas. Surg Neurol. 1986; 25:269–75.

7. Westwick HJ, Giguere JF, Shamji MF. Incidence and prognosis of spinal hemangioblastoma: a Surveillance Epidemiology and End Results study. Neuroepidemiology. 2016; 46:14–23.

8. Nguyen HS, Doan NB, Gelsomino M, et al. Intracranial hemangioblastoma: a SEER-based analysis 2004-2013. Oncotarget. 2018; 9:28009–15.

9. Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastomas of the central nervous system: a 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989; 70:24–30.

10. Conway JE, Chou D, Clatterbuck RE, Brem H, Long DM, Rigamonti D. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery. 2001; 48:55–62.

11. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003; 361:2059–67.

12. Glasker S, Bender BU, Apel TW, et al. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 1999; 67:758–62.

13. Lonser RR, Butman JA, Huntoon K, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2014; 120:1055–62.

14. Doyle LA, Fletcher CD. Peripheral hemangioblastoma: clinicopathologic characterization in a series of 22 cases. Am J Surg Pathol. 2014; 38:119–27.

15. Nonaka D, Rodriguez J, Rosai J. Extraneural hemangioblastoma: a report of 5 cases. Am J Surg Pathol. 2007; 31:1545–51.

16. Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990; 77:1151–63.

17. Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005; 103:495–511.

18. Yousef A, Rutkowski MJ, Yalcin CE, Eren OC, Caliskan I, Tihan T. Sporadic and Von-Hippel Lindau disease-associated spinal hemangioblastomas: institutional experience on their similarities and differences. J Neurooncol. 2019; 143:547–52.

19. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011; 19:617–23.

20. Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991; 28:443–7.

21. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988; 332:268–9.

22. Knudson AG Jr, Strong LC, Anderson DE. Heredity and cancer in man. Prog Med Genet. 1973; 9:113–58.

23. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22:4991–5004.

24. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998; 95:993–8.

25. Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature. 2010; 465:577–83.

26. Tang N, Mack F, Haase VH, Simon MC, Johnson RS. pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol. 2006; 26:2519–30.

27. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. Science. 2001; 292:468–72.

28. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292:464–8.

29. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001; 98:9630–5.

30. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011; 365:537–47.

31. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011; 117:e207–17.

32. Favier J, Gimenez-Roqueplo AP. Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab. 2010; 24:957–68.

33. Li M, Kim WY. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med. 2011; 15:187–95.

34. Glasker S, Bender BU, Apel TW, et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 2001; 70:644–8.

35. Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998; 58:504–8.

36. Shankar GM, Taylor-Weiner A, Lelic N, et al. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014; 2:167.

37. Takayanagi S, Mukasa A, Tanaka S, et al. Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. Neuro Oncol. 2017; 19:1228–36.

38. Jagannathan J, Lonser RR, Smith R, DeVroom HL, Oldfield EH. Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2008; 108:210–22.

39. Glasker S, Kruger MT, Klingler JH, et al. Hemangioblastomas and neurogenic polyglobulia. Neurosurgery. 2013; 72:930–5.

40. Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood. 1998; 92:3388–93.

41. Roonprapunt C, Silvera VM, Setton A, Freed D, Epstein FJ, Jallo GI. Surgical management of isolated hemangioblastomas of the spinal cord. Neurosurgery. 2001; 49:321–7.

42. Chu BC, Terae S, Hida K, Furukawa M, Abe S, Miyasaka K. MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings. AJNR Am J Neuroradiol. 2001; 22:206–17.

43. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003; 98:82–94.

44. Ene CI, Morton RP, Ferreira M Jr, Sekhar LN, Kim LJ. Spontaneous hemorrhage from central nervous system hemangioblastomas. World Neurosurg. 2015; 83:1180.

45. Glasker S, Van Velthoven V. Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery. 2005; 57:71–6.

46. de San Pedro JR, Rodriguez FA, Niguez BF, et al. Massive hemorrhage in hemangioblastomas literature review. Neurosurg Rev. 2010; 33:11–26.

47. Ho VB, Smirniotopoulos JG, Murphy FM, Rushing EJ. Radiologic-pathologic correlation: hemangioblastoma. AJNR Am J Neuroradiol. 1992; 13:1343–52.

48. Parizel PM, Baleriaux D, Rodesch G, et al. Gd-DTPA-enhanced MR imaging of spinal tumors. AJR Am J Roentgenol. 1989; 152:1087–96.

49. Ganti SR, Silver AJ, Hilal SK, Mawad ME, Sane P. Computed tomography of cerebellar hemangioblastomas. J Comput Assist Tomogr. 1982; 6:912–9.

50. Raz E, Zagzag D, Saba L, et al. Cyst with a mural nodule tumor of the brain. Cancer Imaging. 2012; 12:237–44.

51. Ganeshan D, Menias CO, Pickhardt PJ, et al. Tumors in von Hippel-Lindau syndrome: from head to toe-comprehensive state-ofthe-art review. Radiographics. 2018; 38:849–66.

52. Commins DL, Hinton DR. Cytologic features of hemangioblastoma: comparison with meningioma, anaplastic astrocytoma and renal cell carcinoma. Acta Cytol. 1998; 42:1104–10.

53. Wang X, Haines GK 3rd, Mehrotra M, Houldsworth J, Si Q. Primary hemangioblastoma of the kidney with molecular analyses by next generation sequencing: a case report and review of the literature. Diagn Pathol. 2022; 17:34.

54. Shin Y, Kim S, Lee HW, Bang H, Suh YL. Supratentorial hemangioblastoma with unusual features. Korean J Pathol. 2014; 48:462–5.

55. Hasselblatt M, Jeibmann A, Gerss J, et al. Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases. Neuropathol Appl Neurobiol. 2005; 31:618–22.

56. Wippold FJ 2nd, Perry A, Lennerz J. Neuropathology for the neuroradiologist: rosenthal fibers. AJNR Am J Neuroradiol. 2006; 27:958–61.

57. Zec N, Cera P, Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery. 1991; 29:34–7.

58. Carney EM, Banerjee P, Ellis CL, et al. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol. 2011; 35:262–7.

59. Hoang MP, Amirkhan RH. Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma. Am J Surg Pathol. 2003; 27:1152–6.

60. Rivera AL, Takei H, Zhai J, Shen SS, Ro JY, Powell SZ. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology. 2010; 30:580–5.

61. Weinbreck N, Marie B, Bressenot A, et al. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol. 2008; 32:1051–9.

62. Polydorides AD, Rosenblum MK, Edgar MA. Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med. 2007; 131:641–5.

63. Hufnagel TJ, Kim JH, True LD, Manuelidis EE. Immunohistochemistry of capillary hemangioblastoma. Immunoperoxidase-labeled antibody staining resolves the differential diagnosis with metastatic renal cell carcinoma, but does not explain the histogenesis of the capillary hemangioblastoma. Am J Surg Pathol. 1989; 13:207–16.

64. Proescholdt MA, Mayer C, Kubitza M, et al. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro Oncol. 2005; 7:465–75.

65. Barresi V, Vitarelli E, Branca G, Antonelli M, Giangaspero F, Barresi G. Expression of brachyury in hemangioblastoma: potential use in differential diagnosis. Am J Surg Pathol. 2012; 36:1052–7.

66. Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor. Mod Pathol. 1989; 2:638–51.

67. Yang Y, Gao H, Zhen T, et al. Hemangioblastoma: clinicopathologic study of 42 cases with emphasis on TFE3 expression. Am J Transl Res. 2020; 12:4498–510.

68. Wizigmann-Voos S, Plate KH. Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol. 1996; 11:1049–61.

69. Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018; 136:181–210.

70. Venneti S, Boateng LA, Friedman JR, et al. MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. Brain Pathol. 2012; 22:522–9.

71. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005; 18:788–94.

72. Sangoi AR, Karamchandani J, Kim J, Pai RK, McKenney JK. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010; 17:377–93.

73. Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Marchal Bressenot A, Gauchotte G. Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics. J Neuropathol Exp Neurol. 2017; 76:289–98.

74. Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015; 130:441–3.

75. Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002; 94:1057–68.

76. Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol. 1991; 22:84–91.

77. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013; 45:131–2.

78. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125:651–8.

79. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013; 45:180–5.

80. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014; 27:390–5.

81. Yoshida A, Tsuta K, Ohno M, et al. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol. 2014; 38:552–9.

82. Fouladi M, Helton K, Dalton J, et al. Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer. 2003; 98:2232–44.

83. Vege KD, Giannini C, Scheithauer BW. The immunophenotype of ependymomas. Appl Immunohistochem Mol Morphol. 2000; 8:25–31.

84. Tihan T, Ersen A, Qaddoumi I, et al. Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study. Am J Surg Pathol. 2012; 36:43–55.

85. Ligon KL, Alberta JA, Kho AT, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004; 63:499–509.

86. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45:602–12.

87. Nakagawa Y, Perentes E, Rubinstein LJ. Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol. 1986; 72:15–22.

88. Schweizer L, Thierfelder F, Thomas C, et al. Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. Acta Neuropathol. 2020; 140:893–906.

89. Ramani B, Gupta R, Wu J, et al. The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. Acta Neuropathol. 2020; 140:907–17.

90. Koch CA, Mauro D, Walther MM, et al. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol. 2002; 13:17–27.

91. Koga Y, Hamada S, Saito H, Akai T, Kuroda S. Intracranial, intraparenchymal capillary hemangioma: case report. NMC Case Rep J. 2020; 7:43–6.

92. Fish C, Sy J, Wong J. High mitotic activity in a capillary hemangioma of the cauda equina: case report and review of the literature. Clin Neuropathol. 2020; 39:135–8.

93. Kasukurthi R, Ray WZ, Blackburn SL, Lusis EA, Santiago P. Intramedullary capillary hemangioma of the thoracic spine: case report and review of the literature. Rare Tumors. 2009; 1:e10.

94. Dornbos D 3rd, Kim HJ, Butman JA, Lonser RR. Review of the Neurological Implications of von Hippel-Lindau Disease. JAMA Neurol. 2018; 75:620–7.

95. Kano H, Shuto T, Iwai Y, et al. Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study. J Neurosurg. 2015; 122:1469–78.

96. Huang Y, Chan L, Bai HX, et al. Assessment of care pattern and outcome in hemangioblastoma. Sci Rep. 2018; 8:11144.

97. Asthagiri AR, Mehta GU, Zach L, et al. Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro Oncol. 2010; 12:80–6.

98. Ammerman JM, Lonser RR, Dambrosia J, Butman JA, Oldfield EH. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg. 2006; 105:248–55.

99. Miyagami M, Katayama Y, Nakamura S. Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas. Brain Tumor Pathol. 2000; 17:111–20.

100. Binderup ML, Jensen AM, Budtz-Jorgensen E, Bisgaard ML. Survival and causes of death in patients with von Hippel-Lindau disease. J Med Genet. 2017; 54:11–8.